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Abstract
Background: The benefits of chemotherapy in node-negative, hormone receptor-positive, and human epidermal
growth factor receptor 2 (HER2)-negative breast cancer patients with the 21-gene recurrence score (RS) of 18–30,
particularly those with RS 26–30, are not known.
Methods: Using the Surveillance, Epidemiology, and End Results (SEER) data, we retrospectively identified 29,137
breast cancer patients with the 21-gene RS of 18–30 diagnosed between 2004 and 2015. Mortality risks according to
the RS and chemotherapy use were compared by the Kaplan-Meier method and Cox’s proportional hazards model.
Results: Among the breast cancer patients with the RS 18–30, 21% of them had RS 26–30. Compared to breast cancer
patients with RS 18–25, patients with RS 26–30 had more aggressive tumor characteristics and chemotherapy use and
increased risk of breast cancer-specific mortality and overall mortality. In breast cancer patients who were aged ≤ 70
years and had RS of 26–30, chemotherapy administration was associated with a 32% lower risk of breast cancer-specific
mortality (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.47–0.99) and a 42% lower risk of overall mortality (HR,
0.58; 95% CI, 0.44–0.76). Survival benefits were most pronounced in breast cancer patients who were younger or had
grade III tumor.
Conclusions: The 21-gene RS of 18–30 showed heterogeneous outcomes, and the RS 26–30 was a significant
prognostic factor for an increased risk of mortality. Adjuvant chemotherapy could improve the survival of node-
negative, hormone receptor-positive, and HER2-negative breast cancer patients with the 21-gene RS 26–30 and should
be considered for patients, especially younger patients or patients with high-grade tumors.
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Introduction
Systemic chemotherapy reduces the risk of recurrence
and mortality in estrogen receptor (ER) and/or proges-
terone receptor (PR)-positive breast cancer patients irre-
spective of lymph node status [1]. However, the benefits
of chemotherapy are not experienced by all breast can-
cer patients, leading to a need to identify patients who
are more likely to benefit from adjuvant chemotherapy.
The 21-gene recurrence score (RS) assay (Oncotype
DX®; Genomic Health, Inc., Redwood City, CA) available
since 2004 is one of the promising tools to guide treat-
ment decisions in hormone receptor-positive and human
epidermal growth factor receptor 2 (HER2)-negative
breast cancer patients [2, 3]. Based on the 21-gene RS
assay, patients are classified into high (score ≥ 31), inter-
mediate (score 18–30), and low (score ≤ 17) risk. Studies
found that patients in the high-risk group of RS ≥ 31 had
a significant benefit from chemotherapy [4], while patients
with the RS < 11 or 11–25 who were treated with
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Table 1 Demographic and clinicopathological characteristics of study population
2010–2015 dataset (n = 19,791) 2004–2009 dataset (n = 9346)
RS 18–25
[n = 15,731; No. (%)]
RS 26–30
[n = 4060; No. (%)]
P RS 18–25
[n = 7401; No. (%)]
RS 26–30
[n = 1945; No. (%)]
P
Year of diagnosis
2004–2005 – – 567 (7.7) 155 (8.0) 0.421
2006–2007 – – 2522 (34.1) 689 (35.4)
2008–2009 – – 4312 (58.3) 1101 (56.6)
2010–2011 4748 (30.2) 1243 (30.6) 0.797 – –
2012–2013 5229 (33.2) 1329 (32.7) – –
2014–2015 5754 (36.6) 1488 (36.7) – –
Age at diagnosis (years)
≤ 50 3836 (24.4) 923 (22.7) 0.025 2340 (31.6) 539 (27.7) 0.003
51–60 4924 (31.3) 1239 (30.5) 2456 (33.2) 654 (33.6)
61–70 4990 (31.7) 1378 (33.9) 1971 (26.6) 557 (28.6)
> 70 1981 (12.6) 520 (12.8) 634 (8.6) 195 (10.0)
Race/ethnicity
White 12,946 (82.3) 3263 (80.4) 0.018 6299 (85.1) 1662 (85.5) 0.737
Black 1296 (8.2) 391 (9.6) 506 (6.8) 139 (7.2)
Other* 1405 (8.9) 386 (9.5) 561 (7.6) 137 (7.0)
Missing 84 (0.5) 20 (0.5) 35 (0.5) 7 (0.4)
History of cancer
No 13,960 (88.7) 3551 (87.5) 0.023 6654 (89.9) 1764 (90.7) 0.302
Yes 1771 (11.3) 509 (12.5) 747 (10.1) 181 (9.3)
Marital status
Married 9819 (62.4) 2473 (60.9) 0.004 4924 (66.5) 1259 (64.7) 0.215
Single 2105 (13.4) 630 (15.5) 885 (12.0) 255 (13.1)
Other† 3078 (19.6) 786 (19.4) 1333 (18.0) 372 (19.1)
Missing 729 (4.6) 171 (4.2) 259 (3.5) 59 (3.0)
Histologic type
Ductal 11,490 (73.0) 3226 (79.5) < 0.001 5446 (73.6) 1556 (80.0) < 0.001
Lobular 2251 (14.3) 391 (9.6) 897 (12.1) 161 (8.3)
Mixed ductal-lobular 1818 (11.6) 394 (9.7) 960 (13.0) 202 (10.4)
Other 172 (1.1) 49 (1.2) 98 (1.3) 26 (1.3)
Tumor stage
T1b 3535 (22.5) 801 (19.7) < 0.001 1789 (24.2) 409 (21.0) < 0.001
T1c 8271 (52.6) 2112 (52.0) 4217 (57.0) 1070 (55.0)
T2 3698 (23.5) 1091 (26.9) 1339 (18.1) 446 (22.9)
T3 227 (1.4) 56 (1.4) 56 (0.8) 20 (1.0)
Grade
I 3774 (24.0) 486 (12.0) < 0.001 1795 (24.3) 251 (12.9) < 0.001
II 8990 (57.2) 2087 (51.4) 4145 (56.0) 1007 (51.8)
III 2644 (16.8) 1434 (35.3) 1233 (16.7) 636 (32.7)
Missing 323 (2.1) 53 (1.3) 228 (3.1) 51 (2.6)
ER/PR status
+/+ 13,842 (88.0) 3164 (77.9) < 0.001 6389 (86.3) 1459 (75.0) < 0.001
+/− 1872 (11.9) 885 (21.8) 993 (13.4) 478 (24.6)
−/+ 17 (0.1) 11 (0.3) 19 (0.3) 8 (0.4)
Park et al. Breast Cancer Research          (2019) 21:110 Page 2 of 11
endocrine therapy alone had excellent survival outcomes
without chemotherapy in the Trial Assigning Individual-
ized Options for Treatment (TAILORx) trial [5, 6].
Although patients with the intermediate 21-gene RS of
18–30 seemed to have no clinical benefits from chemother-
apy in previous studies [3, 7, 8], young women of ≤ 50 years
old with the RS 16–25 who received chemotherapy had
lower distant recurrence rates than women who did not re-
ceive chemotherapy [6]. A recent study using the National
Cancer Data Base (NCDB) also found that combination of
chemotherapy and hormone therapy was associated with a
lower risk of overall mortality in node-negative breast can-
cer patients with the RS 18–25 as well as those with the RS
26–30 than patients who did not receive chemotherapy [9].
However, this study included older patients (> 70 years of
age) and those with very small tumors of ≤ 0.5 cm, or favor-
able histologies, for whom the National Comprehensive
Cancer Network (NCCN) clinical practice guidelines for
breast cancer do not recommend multigene assays [10];
therefore, more specified analyses focusing on an inter-
mediate RS group are required.
Given that the uncertainty of chemotherapy benefits re-
mains in intermediate-risk patients, especially with the RS
of 26–30 in hormone receptor-positive, HER2-negative,
and node-negative breast cancers, we investigated whether
adjuvant chemotherapy was associated with breast cancer-
specific mortality and overall mortality in breast cancer
patients with the RS 18–30, particularly among those
aged ≤ 70 years with the RS 26–30.
Patients and methods
The Surveillance, Epidemiology, and End Results (SEER)
database
Since 1973, the SEER has collected cancer incidence
and survival data, including patient demographics;
tumor characteristics of primary site, grade, and stage
at diagnosis; and first course of treatments from 18
population-based cancer registries. The SEER registry
has also collected ER and PR status of breast cancer
since 1990 and HER2 status since 2010. All breast can-
cers diagnosed between 2004 and 2015 (excluding
cases reported by the Alaska Native Tumor Registry)
were linked to the 21-gene RS data provided by the Gen-
omic Health Clinical Laboratory [11]. To maximize the
use of Oncotype DX data and have longer follow-up time,
we included all 21-gene RS data since its first collection in
2004. We obtained permission to use the SEER custom
data with additional radiation therapy and chemotherapy
information and the 21-gene RS data.
Study population
We identified 111,635 breast cancer cases with the 21-
gene RS in the SEER 18 database from 2004 to 2015. We
first excluded male breast cancer patients and cases
identified at death/autopsy or through death certificate
only (Additional file 1: Figure S1). Based on the NCCN
guidelines for use of multigene assay [10], we also ex-
cluded cases with at least one of the following conditions:
tumors with non-epithelial origin including sarcoma
(International Classification of Diseases for Oncology, 3rd
Edition, ICD-O-3 > 8800), tubular (8211), mucinous
(8453, 8480, and 8481), and papillary (8050, 8260, and
8503) subtypes; T0-T1a or T4 stage; lymph node-positive
(≥N1mi); distant metastasis (M1) or unknown stage at
diagnosis; ER/PR-negative or unknown ER/PR status; or
cases whose 21-gene RS results were obtained > 12
months after breast cancer diagnosis. In addition, we
excluded breast cancer cases with the 21-gene RS < 18
(low-risk category) or > 30 (high-risk category). Because
HER2 status was available from 2010, we divided the study
population into two groups based on time, 2004–2009
and 2010–2015. In the 2010–2015 dataset, we further ex-
cluded breast cancer cases whose HER2 status was
Table 1 Demographic and clinicopathological characteristics of study population (Continued)
2010–2015 dataset (n = 19,791) 2004–2009 dataset (n = 9346)
RS 18–25
[n = 15,731; No. (%)]
RS 26–30
[n = 4060; No. (%)]
P RS 18–25
[n = 7401; No. (%)]
RS 26–30
[n = 1945; No. (%)]
P
Type of surgery
Breast-conservation surgery 10,806 (68.7) 2747 (67.7) 0.207 5199 (70.3) 1326 (68.2) 0.076
Mastectomy 4925 (31.3) 1313 (32.3) 2202 (29.8) 619 (31.8)
Radiation therapy
No or unknown 6268 (39.8) 1834 (45.2) < 0.001 3038 (41.1) 853 (43.9) 0.025
Yes 9463 (60.2) 2226 (54.8) 4363 (59.0) 1092 (56.1)
Chemotherapy
No or unknown 11,832 (75.2) 1807 (44.5) < 0.001 5044 (68.2) 865 (44.5) < 0.001
Yes 3899 (24.8) 2253 (55.5) 2357 (31.9) 1080 (55.5)
RS recurrence score, No. number, ER estrogen receptor, PR progesterone receptor
*Other race includes American Indian, Alaska Native, and Asian or Pacific Islander
†Other marital status includes separated, divorced, and widowed categories
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positive, borderline, or unknown. The final analytic co-
horts consisted of 9346 breast cancer patients in 2004–
2009 dataset and 19,791 patients in 2010–2015 dataset.
Because of our de-identified data release from the SEER
program and study completion in accordance with the
SEER data-use agreement, this study was exempted from
the Institutional Review Board approval.
Clinicopathological information and outcomes
The SEER data provided patient’s demographics, such as
age at cancer diagnosis; race/ethnicity; marital status;
history of other cancer; tumor characteristics including
morphology, stage, grade, and ER/PR status; and first
course of treatment—type of surgery (breast-conserva-
tion surgery and mastectomy), radiation therapy (yes
and no/unknown), and chemotherapy (yes and no/un-
known). We defined breast cancer histology: ductal
(ICD-O-3, 8500), lobular (8520), mixed ductal-lobular
(8522, 8523, and 8524), and other type.
Underlying causes of death and durations of survival
in the SEER registries were ascertained through linkage
to the state death certificates and the National Death
Index from the National Center for Health Statistics
[12]. We used these variables recorded in the SEER data-
base for calculating breast cancer-specific survival and
overall survival.
Fig. 1 Breast cancer-specific and overall survival curves according to the 21-gene recurrence score (RS). a Breast cancer-specific survival and b
overall survival in 2004–2015 (n = 29,137). c Breast cancer-specific survival and d overall survival in 2010–2015 (n = 19,791). e Breast cancer-specific
survival and f overall survival in 2004–2009 (n = 9346)
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Statistical analysis
We conducted analyses in the 2004–2009 and 2010–2015
(HER2-negative case only) dataset, separately, and the
2004–2015 combined datasets. Based on cutoffs in the
TAILORx trial [13], we categorized patients into the 21-
gene RS 18–25 and 26–30 groups and compared demo-
graphic and clinicopathological characteristics: differences
in means for continuous variables and percentages for
categorical variables between two groups were tested
using t test and chi-square test, respectively. Survival
curves were plotted by the Kaplan-Meier method and
differences in survival time were calculated by the
log-rank test.
Person-months of follow-up were calculated from the
date of breast cancer diagnosis to date of death, known
last follow-up, or follow-up end date (December 31,
2015), whichever occurred first. Hazard ratios (HRs) and
95% confidence intervals (CIs) for breast cancer-specific
and all-cause mortality were estimated by the Cox’s pro-
portional hazards model with person-months as time
scale. A missing category was created for race/ethnicity
(0.5%), marital status (4.2%), and grade (2.3%). We ex-
amined age-adjusted and multivariate models adjusting
for age at diagnosis, calendar year of breast cancer diag-
nosis (2-year interval), race/ethnicity (White, Black, and
others), marital status (married and single/other), history
of cancer (yes and no), histologic type (ductal, lobular, and
mixed ductal-lobular/other), tumor stage (T1b, T1c, and
T2–3), grade (I, II, and III), and ER/PR status (ER+/PR+,
ER+/PR−, and ER−/PR+), surgery (breast-conservation
surgery and mastectomy), radiation therapy (yes, and no/
unknown), and chemotherapy (yes and no/unknown). We
also calculated the mortality risk by chemotherapy status
in patients who had the 21-gene RS 26–30 and were ≤ 70
years old. We conducted sensitivity analyses in the 2010–
2015 dataset by including breast cancer cases with HER2
positive, borderline, or unknown.
Breast cancer cases were generated and exported using
SEER*Stat software version 8.3.5 (https://seer.cancer.gov/
seerstat). All statistical analyses were performed using
Table 2 Hazard ratios (HR) for breast cancer-specific and overall mortality by the 21-gene RS
Breast cancer-specific mortality Overall mortality
RS 18–25
(Reference)
RS 26–30
[HR (95% CI)]
RS 18–25
(Reference)
RS 26–30
[HR (95% CI)]
2004–2015 dataset (n = 29,137)
No. of events 249 141 754 292
Age-adjusted model 1.00 2.17 (1.76 to 2.67) 1.00 1.43 (1.25 to 1.64)
Age- and clinicopathological factor-adjusted model 1.00 1.81 (1.46 to 2.24) 1.00 1.32 (1.15 to 1.52)
Age- and clinicopathological and treatment factor-adjusted model 1.00 1.81 (1.46 to 2.26) 1.00 1.37 (1.19 to 1.58)
Continuous RS in age- and clinicopathological and treatment
factor-adjusted model*
1.09 (1.06 to 1.12)/1-unit RS 1.05 (1.03 to 1.07)/1-unit RS
2010–2015 dataset (n = 19,791)
No. of events 81 49 271 104
Age-adjusted model 1.00 2.35 (1.65 to 3.36) 1.00 1.46 (1.16 to 1.83)
Age- and clinicopathological factor-adjusted model 1.00 1.84 (1.27 to 2.67) 1.00 1.27 (1.01 to 1.61)
Age- and clinicopathological and treatment factor-adjusted model 1.00 1.83 (1.25 to 2.69) 1.00 1.28 (1.00 to 1.63)
Continuous RS in age- and clinicopathological and treatment
factor-adjusted model*
1.12 (1.06 to 1.18)/1-unit RS 1.05 (1.02 to 1.08)/1-unit RS
2004–2009 dataset (n = 9346)
No. of events 168 92 483 188
Age-adjusted model 1.00 2.08 (1.61 to 2.68) 1.00 1.42 (1.20 to 1.68)
Age- and clinicopathological factor-adjusted model 1.00 1.79 (1.38 to 2.33) 1.00 1.35 (1.14 to 1.61)
Age- and clinicopathological and treatment factor-adjusted model 1.00 1.80 (1.38 to 2.36) 1.00 1.41 (1.18 to 1.69)
Continuous RS in age- and clinicopathological and treatment
factor-adjusted model*
1.07 (1.04 to 1.11)/1-unit RS 1.05 (1.03 to 1.07)/1-unit RS
Age at diagnosis is used by categorization into ≤ 50, 51–60, 61–70, and > 70 years. Adjusted clinicopathological factors are year of diagnosis (2004–2005, 2006–
2007, 2008–2009 in 2004–2009 dataset and 2010–2011, 2012–2013, and 2014–2015 in 2010–2015 dataset), race/ethnicity (White, Black, and other), history of
cancer (no and yes), marital status (married and single/other), histologic type (ductal, lobular, and mixed ductal-lobular/other), tumor stage (T1b, T1c, and T2–3),
grade (I, II, III, and missing), and ER/PR status (both ER/PR-positive and either ER/PR-positive). Treatment factors are type of surgery (breast-conservation surgery
and mastectomy), radiation therapy (no/unknown and yes), and chemotherapy (no/unknown and yes)
RS recurrence score, HR hazard ratio, CI confidence interval, No. number
*The 21-gene RS is entered as a continuous variable into Cox’s hazard models adjusting for age at diagnosis and clinicopathological and treatment factors. HR per
1 unit increase in RS
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SAS software version 9.4 (SAS Institute Inc., Cary, NC),
and a P value < 0.05 was considered statistically significant
for 2-sided tests.
Results
Mortality risk according to the 21-gene RS
There were 19,791 breast cancer patients in the 2010–
2015 (mean follow-up 32months) and 9346 patients in
the 2004–2009 dataset (mean follow-up 89months;
Table 1). In both datasets, 21% of patients had the 21-
gene RS of 26–30. The distribution of the 21-gene RS was
not different between the 2010–2015 and 2004–2009
datasets (Additional file 2: Figure S2). Compared to pa-
tients with the RS 18–25, those with the 21-gene RS 26–
30 were more likely to be older, non-White, not married,
have ductal histology, advanced tumor stage, higher grade
tumor, or frequent loss of ER or PR, and receive chemo-
therapy, but no/unknown radiation therapy.
Patients with the RS 26–30 in the 2004–2015 dataset
had significantly worse breast cancer-specific survival and
overall survival compared to those with the RS 18–25
(Fig. 1a, b). When the survival was examined in the 2010–
2015 and 2004–2009 dataset, separately, we found similar
results: poor survival in women with the RS 26–30 in
each dataset (Fig. 1c–f). Compared to patients with the
RS 18–25, those with the RS 26–30 had an 81% increased
risk of breast cancer-specific mortality (HR, 1.81; 95% CI,
1.46–2.26) and a 37% increased risk of overall mortality
(HR,1.37; 95% CI, 1.19–1.58; Table 2) after adjusting for
potential confounders, including age at diagnosis, clinico-
pathological characteristics, and treatments. Similar re-
sults were consistently observed when we analyzed the
2010–2015 and 2004–2009 dataset, separately.
Fig. 2 Breast cancer-specific and overall survival curves according to the 21-gene RS in sensitivity analyses that included breast cancer with HER2-
positive, borderline, and unknown status in 2010–2015 (n = 20,943). a Breast cancer-specific survival and b overall survival according to RS groups.
c Breast cancer-specific survival and d overall survival according to RS group by HER2 status
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In sensitivity analyses that included breast cancer with
HER2-positive, borderline, or unknown status in 2010–
2015 dataset (n = 1152, 5.5% of total breast cancer cases),
similar results were found: patients with the RS 26–30 had
poor survival than those with the RS 18–25 (Fig. 2). Also,
after further adjusting for HER2 status in multivariate
models, there was a 78% and 31% increased risk of breast
cancer-specific and overall mortality, respectively, in pa-
tients with the RS 26–30 compared to those with the RS
18–25 (Additional file 3; Table S1).
Chemotherapy and survival of patients with the RS 26–30
and age ≤ 70 years
Among 5290 breast cancer patients aged ≤ 70 years with
the RS 26–30, 3130 (59%) patients received adjuvant
chemotherapy. Patients who received chemotherapy
were more likely to be younger and have advanced tumor
stage, grade III, and also receiving radiation therapy than
those who did not (Additional file 4: Table S2). In the
2004–2015 dataset, breast cancer-specific survival did not
significantly differ by chemotherapy use (log-rank
P = 0.089; Fig. 3a). On the other hand, overall sur-
vival rate was significantly higher in patients who re-
ceived chemotherapy than in those who did not
(log-rank P < 0.001; Fig. 3b). When breast cancer-
specific survival by chemotherapy use was examined
in subgroups of age (≤ 56 and 57–70 years old: mean
age = 56 years) and grade (I–II and III), younger pa-
tients of ≤ 56 years (log-rank P = 0.046; Fig. 4a) and
patients with grade III tumor (log-rank P = 0.003;
Fig. 4g) tended to have better survival when they re-
ceived chemotherapy than those who did not. Over-
all survival was consistently higher in patients who
received chemotherapy regardless of their age and
grade (Fig. 4). Similar results were found in analyses
using the 2004–2009 and 2010–2015 data, separately
(data not shown).
In multivariate Cox’s hazard models, adjuvant chemo-
therapy was associated with significantly decreased risks
of breast cancer-specific mortality (HR, 0.68; 95% CI,
0.47–0.99) and overall mortality (HR, 0.58; 95% CI,
0.44–0.76) after adjusting for demographic, clinicopatho-
logical, and treatment factors in the 2004–2015 dataset
(Table 3). Similar, but statistically not significant, associ-
ations were observed in analyses of the 2010–2015 and
2004–2009 datasets, separately.
Discussion
In this study, we found that the 21-gene RS was associ-
ated with an increased risk of breast cancer-specific and
overall mortality in breast cancer patients who had the
RS18–30. In addition, our study suggested that adjuvant
chemotherapy was associated with better survival of pa-
tients aged ≤ 70 years with the 21-gene RS 26–30. Inter-
estingly, we found that breast cancer-specific and overall
survival rates in patients with the RS 26–30 and who re-
ceived chemotherapy were higher in younger versus
older patients and those with grade III versus grade I–II
tumor. Additional clinical parameters such as Ki-67 pro-
liferative index or expression levels of hormone receptor,
which represent tumor biology or subtype, may provide
additional information to aid a treatment decision for
this subgroup of breast cancer patients [14, 15].
Since the introduction of multigene assays, use of the
21-gene RS test in clinical practice has gradually in-
creased and is anticipated to be widely utilized as a treat-
ment decision aid in ER-positive and HER2-negative
early-stage breast cancer patients [16, 17]. However,
Fig. 3 Breast cancer-specific and overall survival curves according to chemotherapy use in patients aged ≤ 70 years old with the RS 26–30 in the
SEER 2004–2015 dataset (n = 5290). a Breast cancer-specific survival and b overall survival
Park et al. Breast Cancer Research          (2019) 21:110 Page 7 of 11
Fig. 4 (See legend on next page.)
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clinicians should be aware that the 21-gene RS is a rela-
tive numeric calculated, not an absolute parameter for
predicting patient prognosis. In previous clinical trials
that validated the 21-gene RS assay [2, 3], the preva-
lence of patients with the RS 18–30 classified as an
intermediate-risk group was 21–22%. However, the
prevalence of breast cancer with the RS 18–30 was
higher (33%) in a nation-wide cancer database in the
USA [9]. The prevalence of the intermediate RS
group varied across countries: from 20.0% in the Japa-
nese to 40.7% in the Israeli with early-stage breast
cancer [7, 18, 19]. Among breast cancer patients with
intermediate risk of the RS 18–30, approximately one
out of five patients had the RS of 26–30 in our study
using the SEER and the previous studies [7, 9].
Similarly to previous studies [7, 9], we observed that
the intermediate-risk group, RS 18–30, was heteroge-
neous in their demographic and clinicopathological
characteristics. Compared to patients with the RS 18–25,
breast cancer patients with the RS 26–30 were more
likely to have aggressive tumor: larger size, higher grade,
and single hormone receptor positivity. Also, we found
that a 5% increased risk of overall mortality per 1 unit
increase in the RS among breast cancer patients with the
RS 18–30, which was consistent with a previous finding
[9]. Breast cancer-specific mortality was increased by 9%
per 1 unit increase in the RS among our study popula-
tion with the RS 18–30.
As expected [20], chemotherapy-treated patients had
more aggressive clinicopathological features. However,
Table 3 Hazard ratios (HR) for breast cancer-specific and overall mortality by chemotherapy use in patients aged ≤ 70 years old with
the RS 26–30
Breast cancer-specific mortality Overall mortality
No/unknown chemotherapy
(Reference)
Yes chemotherapy
[HR (95% CI)]
No/unknown chemotherapy
(Reference)
Yes chemotherapy
[HR (95% CI)]
2004–2015 dataset (n = 5290)
No. of events 58 62 117 98
Age-adjusted model 1.00 0.76 (0.53 to 1.09) 1.00 0.63 (0.48 to 0.83)
Age- and clinicopathological factor-adjusted
model
1.00 0.66 (0.45 to 0.95) 1.00 0.56 (0.42 to 0.74)
Age- and clinicopathological and treatment
factor-adjusted model
1.00 0.68 (0.47 to 0.99) 1.00 0.58 (0.44 to 0.76)
2010–2015 dataset (n = 3540)
No. of events 22 23 40 40
Age-adjusted model 1.00 0.73 (0.40 to 1.32) 1.00 0.75 (0.48 to 1.18)
Age- and clinicopathological factor-adjusted
model
1.00 0.63 (0.34 to 1.15) 1.00 0.67 (0.43 to 1.05)
Age- and clinicopathological and treatment
factor-adjusted model
1.00 0.64 (0.35 to 1.18) 1.00 0.72 (0.45 to 1.14)
2004–2009 dataset (n = 1750)
No. of events 36 39 77 58
Age-adjusted model 1.00 0.77 (0.49 to 1.23) 1.00 0.56 (0.40 to 0.79)
Age- and clinicopathological factor-adjusted
model
1.00 0.68 (0.43 to 1.09) 1.00 0.50 (0.35 to 0.71)
Age- and clinicopathological and treatment
factor-adjusted model
1.00 0.71 (0.44 to 1.13) 1.00 0.51 (0.36 to 0.72)
Age at diagnosis is used by categorization into ≤ 50, 51–60, and 61–70 years. Adjusted clinicopathological factors are year of diagnosis (2004–2005, 2006–2007,
2008–2009 in 2004–2009 dataset and 2010–2011, 2012–2013, and 2014–2015 in 2010–2015 dataset), race/ethnicity (White, Black, and other), history of cancer (no
and yes), marital status (married and single/other), histologic type (ductal, lobular, and mixed ductal-lobular/other), tumor stage (T1b, T1c, and T2–3), grade (I, II, III,
and missing), and ER/PR status (both ER/PR-positive and either ER/PR-positive). Treatment factors are type of surgery (breast-conservation surgery and
mastectomy) and radiation therapy (no/unknown and yes)
RS recurrence score, HR hazard ratio, CI confidence interval, No. number
(See figure on previous page.)
Fig. 4 Breast cancer-specific and overall survival curves according to chemotherapy use among patients with age≤ 70 years and the RS 26–30,
stratified by age and tumor grade. a Breast cancer-specific survival in patients ≤ 56 years of age, b overall survival in patients ≤ 56 years of age, c breast
cancer-specific survival in patients 57–70 years of age, d overall survival in patients 57–70 years of age, e breast cancer-specific survival in patients with
grade I–II tumor, f overall survival in patients with grade I–II tumor, g breast cancer-specific survival in patients with grade III tumor, and h overall
survival in patients with grade III tumor
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after adjusting for demographic and clinicopathological
factors in our study, chemotherapy was significantly as-
sociated with a lower risk of breast cancer-specific and
overall mortality in patients ≤ 70 years old with the 21-
gene RS 26–30. This suggested that adjuvant chemother-
apy might be beneficial to patients who are ≤ 70 years
old and have the RS 26–30 even though they are classi-
fied as having an intermediate risk of recurrence. The
study by Ibraheem et al. [9] also reported that chemo-
therapy was related to a 32% lower risk of overall mor-
tality in patients with node-negative breast cancer and
the 21-gene RS 26–30. In a re-analysis of the National
Surgical Adjuvant Breast and Bowel Project (NSABP) B-
20 trial excluding presumed HER2-positive cases, signifi-
cantly better distant recurrence-free survival rates were
observed in patients with the 21-gene RS ≥ 26 who re-
ceived chemotherapy [4].
Our study was one of the largest studies examining
the effect of chemotherapy on survival in breast cancer
patients with an intermediate risk for recurrence. The
SEER data which capture > 98% of incident cancer cases
in 18 geographical regions provide a large number of
breast cancer cases with survival outcome and the 21-
gene RS [11, 21]. In addition, we selected our patient
population according to the NCCN practice guidelines
and focused analyses on patients with the RS 26–30,
which will help decision-making for chemotherapy in
patients with the RS 26–30. Our study also has several
limitations mostly related to inherent limitations in the
SEER database: it did not provide information on disease
recurrence, endocrine therapy use, and details of chemo-
therapeutic regimens. Also, receipt of chemotherapy and
radiation therapy was under-reported in the SEER pro-
gram compared to the Medicare claims data restricted
to patients aged ≥ 65 years [22]. Given that systemic
chemotherapy tends to be administered to patients with
better performance status which could not be assessed in
this study, we cannot rule out the possibility of residual
confounding by unmeasured factors in our analyses. In
addition, although the distribution of the 21-gene RS did
not differ between 2010 and 2015 and 2004–2009 dataset,
about 5% of total breast cancer cases had HER2-positive,
borderline, or undetermined status in 2010–2015 dataset
just before the final exclusion step. Given that 1with
HER2-positive were more likely to have the higher
21-gene RS, analyses of 2004–2009 data may have
additional confounding due to lack of HER2 status.
Nevertheless, when we performed sensitivity analyses
including patients with HER2 positive, borderline, or
unknown status in 2010–2015 data, our results did
not change. Another limitation was the lack of infor-
mation on menopausal status. Thus, we could not
examine premenopausal and postmenopausal breast
cancer, separately.
Conclusions
Our findings suggest that adjuvant chemotherapy pro-
vides a significant survival benefit to patients with an
intermediate risk for recurrence, particularly those with
the 21-gene RS 26–30, and particularly for younger pa-
tients and those with high-grade tumors. Given that the
21-gene RS is a promising tool that can guide a chemo-
therapy decision in early-stage breast cancer patients
with hormone receptor-positive and HER2-negative
tumor, a shared-decision making with patients, using the
multigene assay result and discussions about known
risks and benefits of chemotherapy should be warranted
in the era of personalized medicine.
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